Flags

Financial distress

Ironwood Pharmaceuticals

NSQ:IRWD · US46333X1081

BiotechnologySmall

360

Value62

Profit price11

Cash yield50

Owner Earnings Yield98

Dividend Yield1

Sales & asset price88

Price/Sales96

EV / Gross Profit80

Price/Book87

Quality73

Returns on capital97

Return on Capital94

Cash Return on Capital100

Profit margins91

EBIT Margin91

Gross Profitability90

Cash backing67

Accruals34

Owner Earnings Margin100

Growth75

Sales growth70

Profit growth85

Profit Growth96

Long-Term EPS Growth73

Reinvestment51

Price momentum96

Safety38

Debt load9

Debt serviceability59

Refinancing98

Debt Payback20

Liquidity87

Sentiment50

Analyst ratings7

Expectations trend34

Opinion Changes50

Price Target Upside17

Market mood8

Value Creation20/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Ironwood Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded1998

Employees242

Websiteironwoodpharma.com

ISINUS46333X1081

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Pain ManagementGastroenterologyBiotechnologyHealth CarePharmaceutical

Description

Ironwood Pharmaceuticals, Inc. (Ironwood) operates as a biotechnology company. The company is developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. The company is focused on the develo…

Analysis

Quality compounder

Ironwood Pharmaceuticals, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is attractive. The owner-earnings multiple stands at 5.7×; owner earnings: the cash an owner could take out each year.

Growth is solid; the safety picture is stretched. The company scores 20/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ironwood Pharmaceuticals with its peers

AbbVie

NYQ:ABBV

CountryUSA

IndustryBiotechnology

SizeXX-Large

Full Stock Analysis →

ACADIA Pharmaceuticals

NSQ:ACAD

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Vera Therapeutics

NMQ:VERA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

BioCryst Pharmaceuticals

NSQ:BCRX

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Immunic

NAQ:IMUX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

RAPT Therapeutics

NMQ:RAPT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →